DavidMichaelHymanMD

Gynecologic Cancer, Hematologic Oncology

Medical Oncology Fellow Memorial Sloan Kettering Cancer Center

Dr. Hyman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a medical oncologist who specializes in the treatment of gynecologic cancers. My research interests including developmental therapeutics, gynecologic cancer, rare uterine sarcomas, and BRCA-associated ovarian cancer.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Weill Cornell MedicineClass of 2006

PubMed

Journal Articles

Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms
Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
Article Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Sarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer
Hyman, D.M., Spriggs, D.R., JAMA
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C, Invest New Drugs
Join now to see all

Abstracts/Posters

Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant Abstract
David M. Hyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.
2019 ASCO Annual Meeting - 6/1/2019
JAVELIN BRCA/ATM: A phase 2 trial of avelumab (antiâ€“PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
2019 ASCO Annual Meeting - 6/1/2019
Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Eli Lilly's Verzenio Snags First-in-Class FDA Approval for Early Breast Cancer. But Limited Label Poses a ChallengeOctober 13th, 2021
FDA Expands Lilly's ERBITUX® (Cetuximab) Label with Combination of BRAFTOVI® (Encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) After Prior TherapySeptember 28th, 2021
Lilly Presents New Data on Retevmo® (Selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual MeetingApril 11th, 2021
Join now to see all

Member, SEP Working Group, American Society of Clinical Oncology 2011 - Present
Member, Investigational New Drug Committee, Memorial Sloan-Kettering Cancer Center 2011 - Present
Member, Admissions Committee, Weill Cornell Medical College 2010 - Present
Member, Organization of Resident Representatives, AAMC 2010 - Present
Member, Fellow Advisory Group, American Society of Clinical Oncology 2009 - Present